Browsing by Author "Serrano, Laia"

Sort by: Order: Results:

  • Posso, Margarita; Corominas Torres, Josep Maria; Serrano, Laia; Román, Marta; Torá Rocamora, Isabel, 1979-; Domingo, Laia; Romero, Anabel; Quintana, María Jesús; Vernet-Tomás, Maria; Baré, Marisa; Vidal, Carmen; Sánchez, Mar; Saladié, Francina; Natal, Carmen; Ferrer, Joana; Servitja Tormo, Sonia; Sala, Maria; Castells, Xavier; BELE Study Group (Wiley, 2017)
    Women with benign breast diseases (BBD) have a high risk of breast cancer. However, no biomarkers have been clearly established to predict cancer in these women. Our aim was to explore whether estrogen receptor (ER), ...
  • Sabbaghi Mehrjardi, Mohammad Ali; Gil Gómez, Gabriel; Guardia Laguarta, Cristina; Servitja Tormo, Sonia; Arpí Llucià, Oriol; Menendez Romero, Silvia; Arumí, Montserrat; Serrano, Laia; Salido Galeote, Marta; Muntasell i Castellví, Aura, 1972-; Martínez-García, Maria; Tusquets Trias de Bes, Ignacio; Rovira Guerín, Ana; Albanell Mestres, Joan (American Association for Cancer Research (AACR), 2017)
    Purpose: Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance.Experimental Design: ...
  • Hernández Llodrà, Silvia; Juanpere, Nuria; Muga, Silvia de; Lorenzo Perez, Marta; Gil Ortega, Joan; Font Tello, Alba 1990-; Agell, Laia; Albero-González, Raquel; Segalés, Laura; Merino, José; Serrano, Laia; Fumadó Ciutat, Lluis; Cecchini Rosell, Lluís; Lloreta Trull, Josep, 1958- (Impact Journals, 2017)
    TMPRSS2 and SLC45A3 rearrangements may coexist in the same tumor. ERG rearrangements and PTEN loss are concomitant events in prostate cancer (PrCa), and can cooperate in progression. We have reported that mRNA expression ...
  • Mancebo Moreno, Gemma; Solé-Sedeño, Josep Maria; Membrive, Ismael; Taus García, Álvaro; Castells Zaragoza, Marta; Serrano, Laia; Carreras Collado, Ramón; Miralpeix, E. (BMJ Publishing Group, 2021)
    The SARS-CoV-2 (COVID-19) pandemic has significantly impacted the management of patients with gynecologic cancers. Many centers have reduced access to routine visits to avoid crowded waiting areas and specially to reduce ...